Heather Jacene

10PUBLICATIONS
111CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markersConflict of laws (incl. private international law)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 28, 2026
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).

|Jul 27, 2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).

|Apr 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

|Mar 19, 2025
Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.

Meryam Losee, Michael Kavanaugh, Mofei Liu

|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso

|Mar 29, 2024
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Atish D Choudhury, Lucia Kwak, Alexander Cheung

Pageof 2

Frequent Collaborators

3 joint publications

Atish D Choudhury

2 joint publications

John Patrick Pilkington Woll

2 joint publications

Marie-Jeanne Vrancken Peeters

2 joint publications

Gary J R Cook